Cancer immunotherapy could become dramatically more accessible if therapeutic cells can be engineered directly inside patients rather than through costly laboratory manufacturing processes. This paradigm shift would eliminate the weeks-long delays and specialized facilities currently required to create personalized cell therapies for blood cancers.
Researchers successfully demonstrated direct in-body generation of CAR-T cells targeting BCMA (B-cell maturation antigen) using lentiviral delivery in five patients with treatment-resistant multiple myeloma. The approach delivered genetic instructions directly to patients' T cells via injection, programming them to recognize and attack myeloma cells expressing BCMA. No dose-limiting toxicities emerged during the phase 1 safety evaluation, suggesting the technique can avoid the severe inflammatory reactions that sometimes accompany traditional CAR-T therapies.
This represents a potentially transformative advance in cellular immunotherapy delivery. Current CAR-T manufacturing requires extracting patient T cells, genetically modifying them in specialized laboratories over 2-4 weeks, then reinfusing the engineered cells—a process costing hundreds of thousands of dollars and limiting access to major cancer centers. In vivo generation could democratize this powerful treatment approach, making it available in standard oncology practices worldwide. However, this early-stage trial focused primarily on safety rather than efficacy, and the small patient cohort limits broader conclusions. The approach must demonstrate comparable anti-cancer activity to laboratory-manufactured CAR-T cells in larger trials. Additionally, ensuring precise control over which cells receive genetic modification remains a critical challenge for widespread clinical adoption. If successful in larger studies, this technique could fundamentally reshape how we deliver precision cancer immunotherapy.